Oncotelic Therapeutics (OTCQB: OTLC) opens BIO REBOOT registration for its AI-powered PDAOAI drug discovery platform, offering selected projects startup funding and full development support. Two keynote presentations confirmed for Drug Discovery 2026 in Burlingame, CA. #DrugDiscovery #Biotech

NanoViricides (NYSE: NNVC) will present at the NIBA 153rd Investment Conference Oct. 7, 2026. Their lead drug NV-387 is in Phase 2 trials for Ebola and Mpox, with FDA designations for measles treatment. A pipeline worth watching. #Biotech #Antiviral

Telomir Pharmaceuticals (NASDAQ: TELO) raises ~$5.6M in PIPE financing to fund its FDA-cleared Phase 1/2 trial of Telomir-Zn in triple-negative breast cancer. Major shareholder John Paul DeJoria contributed $1M to the raise. #Biotech #Oncology

Okogen receives India's CDSCO authorization to advance the EMERALD Phase 1/2 trial of Treyegen (OKG-0303), a novel single therapy targeting both viral and bacterial acute infectious conjunctivitis. Data expected later this year. #Biotech #Ophthalmology

Lantern Pharma (NASDAQ: LTRN) announces a $4M registered direct offering at $1.09/share, with warrants that could unlock an additional $4M. Proceeds will fuel its AI-driven oncology pipeline. #Biotech #Oncology

NanoViricides (NNVC) launches Phase II trials for NV-387 targeting Mpox and Ebola in the DRC, while securing FDA Orphan Drug and Rare Pediatric Disease designations for measles treatment. The company raised over $12M to fuel its growing antiviral pipeline. #Biotech #Antiviral

VERAXA Biotech (NASDAQ: VRXA) advances its VXA-222 bispecific ADC into preclinical studies after completing discovery-phase collaboration with OmniAb. The 'AND-gate' design targets two tumor antigens simultaneously, aiming for greater cancer-cell selectivity. #Biotech #Oncology

BIOT (Nasdaq: BIOT) has been named authorized representative for IN01, a clinical-stage cancer immunotherapy vaccine, in Japan and China. With 2.5M annual lung cancer diagnoses globally, the stakes are high as BIOT seeks strategic partners in two key markets. #Oncology #Biotech

Quantum BioPharma (NASDAQ: QNTM) is advancing Lucid-MS into Phase 2 trials for multiple sclerosis while its unbuzzd spinout delivers a 7% royalty stream up to $250M. A dual-track strategy targeting both pharma and wellness markets. #Biotech #MultipleSclerosis

Quantum BioPharma (NASDAQ: QNTM) is advancing Lucid-MS into a Phase 2 MS trial while holding a 20% stake and 7% royalty stream in alcohol-metabolism product unbuzzd. A dual pipeline worth watching. #Biotech #MultipleSclerosis

Onco-Innovations (ONCO) advances ONC010 cancer candidate with 99.3% purity API scale-up, CAD$5M institutional financing, and new CFO appointment as it targets a Phase 1 trial in Australia. #Oncology #Biotech

Incannex Healthcare ($IXHL) moves IHL-42X into active clinical execution. The DReAMzz study enrolls ~120 patients across 14 U.S. sites, targeting mid-2027 completion, with $68.4M cash on hand supporting at least 12 months of operations. #Biotech #ClinicalTrials

Regentis Biomaterials (RGNT) is tackling knee cartilage repair's biggest flaw: short-term pain relief without lasting tissue restoration. Their GelrinC hydrogel guides natural hyaline cartilage regeneration, backed by long-term MRI and clinical data. #Orthopedics #Biotech

Biotech leader Philip Ashton-Rickardt says the best scientists know when to change course. 'Flexibility is not failure. Sometimes it means you learned something.' A mindset worth adopting across all of R&D. #Biotech #Leadership